Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 10.41 USD 3.07% Market Closed
Market Cap: 464m USD
Have any thoughts about
Y-mAbs Therapeutics Inc?
Write Note

Intrinsic Value

YMAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one YMAB stock under the Base Case scenario is 15.75 USD. Compared to the current market price of 10.41 USD, Y-mAbs Therapeutics Inc is Undervalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

YMAB Intrinsic Value
15.75 USD
Undervaluation 34%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Y-mAbs Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for YMAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about YMAB?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Y-mAbs Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Y-mAbs Therapeutics Inc

Provide an overview of the primary business activities
of Y-mAbs Therapeutics Inc.

What unique competitive advantages
does Y-mAbs Therapeutics Inc hold over its rivals?

What risks and challenges
does Y-mAbs Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Y-mAbs Therapeutics Inc recently?

Summarize the latest earnings call
of Y-mAbs Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Y-mAbs Therapeutics Inc.

Provide P/S
for Y-mAbs Therapeutics Inc.

Provide P/E
for Y-mAbs Therapeutics Inc.

Provide P/OCF
for Y-mAbs Therapeutics Inc.

Provide P/FCFE
for Y-mAbs Therapeutics Inc.

Provide P/B
for Y-mAbs Therapeutics Inc.

Provide EV/S
for Y-mAbs Therapeutics Inc.

Provide EV/GP
for Y-mAbs Therapeutics Inc.

Provide EV/EBITDA
for Y-mAbs Therapeutics Inc.

Provide EV/EBIT
for Y-mAbs Therapeutics Inc.

Provide EV/OCF
for Y-mAbs Therapeutics Inc.

Provide EV/FCFF
for Y-mAbs Therapeutics Inc.

Provide EV/IC
for Y-mAbs Therapeutics Inc.

Show me price targets
for Y-mAbs Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Y-mAbs Therapeutics Inc?

How accurate were the past Revenue estimates
for Y-mAbs Therapeutics Inc?

What are the Net Income projections
for Y-mAbs Therapeutics Inc?

How accurate were the past Net Income estimates
for Y-mAbs Therapeutics Inc?

What are the EPS projections
for Y-mAbs Therapeutics Inc?

How accurate were the past EPS estimates
for Y-mAbs Therapeutics Inc?

What are the EBIT projections
for Y-mAbs Therapeutics Inc?

How accurate were the past EBIT estimates
for Y-mAbs Therapeutics Inc?

Compare the revenue forecasts
for Y-mAbs Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Y-mAbs Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Y-mAbs Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Y-mAbs Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Y-mAbs Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Y-mAbs Therapeutics Inc with its peers.

Analyze the financial leverage
of Y-mAbs Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Y-mAbs Therapeutics Inc.

Provide ROE
for Y-mAbs Therapeutics Inc.

Provide ROA
for Y-mAbs Therapeutics Inc.

Provide ROIC
for Y-mAbs Therapeutics Inc.

Provide ROCE
for Y-mAbs Therapeutics Inc.

Provide Gross Margin
for Y-mAbs Therapeutics Inc.

Provide Operating Margin
for Y-mAbs Therapeutics Inc.

Provide Net Margin
for Y-mAbs Therapeutics Inc.

Provide FCF Margin
for Y-mAbs Therapeutics Inc.

Show all solvency ratios
for Y-mAbs Therapeutics Inc.

Provide D/E Ratio
for Y-mAbs Therapeutics Inc.

Provide D/A Ratio
for Y-mAbs Therapeutics Inc.

Provide Interest Coverage Ratio
for Y-mAbs Therapeutics Inc.

Provide Altman Z-Score Ratio
for Y-mAbs Therapeutics Inc.

Provide Quick Ratio
for Y-mAbs Therapeutics Inc.

Provide Current Ratio
for Y-mAbs Therapeutics Inc.

Provide Cash Ratio
for Y-mAbs Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Y-mAbs Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Y-mAbs Therapeutics Inc?

What is the current Free Cash Flow
of Y-mAbs Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Y-mAbs Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Y-mAbs Therapeutics Inc

Current Assets 99.1m
Cash & Short-Term Investments 68.1m
Receivables 19.9m
Other Current Assets 11m
Non-Current Assets 21.9m
PP&E 1.1m
Intangibles 2.4m
Other Non-Current Assets 18.4m
Current Liabilities 25.3m
Accounts Payable 7.9m
Accrued Liabilities 17.4m
Non-Current Liabilities 3.2m
Other Non-Current Liabilities 3.2m
Efficiency

Earnings Waterfall
Y-mAbs Therapeutics Inc

Revenue
84.6m USD
Cost of Revenue
-9.4m USD
Gross Profit
75.2m USD
Operating Expenses
-103.6m USD
Operating Income
-28.5m USD
Other Expenses
4.6m USD
Net Income
-23.9m USD

Free Cash Flow Analysis
Y-mAbs Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

YMAB Profitability Score
Profitability Due Diligence

Y-mAbs Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
27/100
Profitability
Score

Y-mAbs Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

YMAB Solvency Score
Solvency Due Diligence

Y-mAbs Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
80/100
Solvency
Score

Y-mAbs Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

YMAB Price Targets Summary
Y-mAbs Therapeutics Inc

Wall Street analysts forecast YMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for YMAB is 21.33 USD with a low forecast of 11.11 USD and a high forecast of 27.3 USD.

Lowest
Price Target
11.11 USD
7% Upside
Average
Price Target
21.33 USD
105% Upside
Highest
Price Target
27.3 USD
162% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for YMAB?

Click here to dive deeper.

Dividends

Y-mAbs Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for YMAB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

YMAB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

464.2m USD

Dividend Yield

0%

Description

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 148 full-time employees. The company went IPO on 2018-09-21. The company is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. The company also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The firm is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Contact

NEW YORK
New York City
230 Park Avenue, Suite 3350
+12128479841.0
www.ymabs.com

IPO

2018-09-21

Employees

148

Officers

CEO, President & Director
Mr. Michael Rossi
Founder, Chief Business Officer & Vice Chairman
Mr. Thomas Gad
Senior VP & Chief Commercial Officer
Ms. Susan Smith
CFO & Treasurer
Mr. Peter P. Pfreundschuh CPA
Senior VP & COO
Mr. Joris Wiel Jan Wilms
Senior VP & CTO
Dr. Torben Lund-Hansen M.Sc., Ph.D.
Show More
Vice President of Investor Relations
Ms. Courtney Dugan
Senior VP & Chief Medical Officer
Dr. Vignesh Rajah M.B.A., MBBS
Chief Development Officer
Dr. Norman D. LaFrance FACNP, FACP, M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one YMAB stock?

The intrinsic value of one YMAB stock under the Base Case scenario is 15.75 USD.

Is YMAB stock undervalued or overvalued?

Compared to the current market price of 10.41 USD, Y-mAbs Therapeutics Inc is Undervalued by 34%.

Back to Top